GLPwatch

A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)

NCT04445181 · Completed

Last updated 2026-05-28

This study examines how common chronic kidney disease is among Canadian adults with type 2 diabetes using data from a large diabetes registry.

Status Completed The study has finished.
Type Observational
Participants 14,873 people
Who can join all sexes
Timeline Started 2020-07 · est. completion 2020-11
Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT04445181 ↗

Description as written by the study sponsor.

In people with type 2 diabetes (T2D), the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with T2D are at a higher risk of having a condition called chronic kidney disease (CKD). In people with CKD, the kidneys become damaged and do not work as they should. People with CKD can have trouble breathing and often have swelling in their arms and legs, and high blood pressure. People who have CKD and T2D are more likely to have other medical problems, such as heart disease. There are many treatments available to patients who have CKD and T2D. But, researchers need more information about how doctors in Canada are deciding which treatment to give these patients. In this study, the researchers will review health information from men and women with T2D who visited a doctor in 2019 and had check-ups for at least 6 months. The health information will be taken from a Canadian registry (or database) owned by LMC Diabetes \& Endocrinology. The registry contains information from people that went to an LMC clinic. In this study, the researchers will learn how many of these people had T2D and CKD. They will learn the treatments these people received, and if they had other related medical problems. The researchers will also use surveys to ask the doctors about why they chose certain treatments.

Treatments tested

Main thing measuredProportion of patients with CKD in a large T2D population
SponsorBayer
Conditions studiedChronic Kidney Disease in Type 2 Diabetes
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04445181 ↗